New combo aims to control mantle cell lymphoma without chemo
NCT ID NCT02682641
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial is testing a combination of two drugs—ibrutinib and rituximab—in 50 people with untreated, slow-growing mantle cell lymphoma. The goal is to see if this drug pair can shrink or eliminate the cancer and keep it from progressing. Researchers will also study the tumor's genetic makeup to better understand who responds best.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ibrutinib (Imbruvica) and rituximab (Rituxan)
What this could lead to
If successful, this combination could offer a highly effective first treatment for people with slow-growing mantle cell lymphoma, potentially leading to long-term disease control without immediate chemotherapy.
What could go wrong
This is a mid-stage trial with only 50 participants, so results may not apply to everyone. The treatment may cause side effects like infections or bleeding, and it is not a cure—patients may need ongoing therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Clínic de Barcelona
Barcelona, Barcelona, 08036, Spain
-
Hospital Clínico de Valencia
Valencia, Valencia, Spain
-
Hospital Costa del Sol
Marbella, Málaga, Spain
-
Hospital General Universitario Santa Lucía
Cartagena, Murcia, Spain
-
Hospital Universitario 12 de Octubre
Madrid, Madrid, 28041, Spain
-
Hospital Universitario Clinico de Salamanca
Salamanca, Spain
-
Hospital Universitario Fundación Alcorcón
Alcorcón, Madrid, Spain
-
Hospital Universitario Mútua Terrassa
Terrassa, Barcelona, Spain
-
Hospital Universitario Ramon y Cajal
Madrid, Madrid, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, Barcelona, Spain
-
Hospital Universitario Virgen del Rocio
Seville, Sevilla, Spain
-
Hospital Universitario de Burgos
Burgos, Burgos, Spain
-
Hospital de la Santa Creu i Sant Pau
Barcelona, Barcelona, Spain
-
Institut Català d'Oncologia
Barcelona, Barcelona, Spain
-
MD Anderson Cancer Center
Madrid, Madrid, Spain